GlassScriptPhysician profile
Roland R Tindle
NPI 1053304105
$509.10
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.90 · 2020: $181 · 2021: $193 · 2022: $43.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $223.79 | 2019-2021 | |
| Novo Nordisk INC | $74.31 | 2019-2021 | |
| Amarin Pharma, INC. | $59.50 | 2020-2021 | |
| Cardiovascular Systems INC. | $43.07 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.34 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $26.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.35 | 2021 | |
| Zyla Life Sciences, INC. | $14.08 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.65 | 2019 | |
| Glaxosmithkline, LLC. | $11.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roland Tindle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.